Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2018 2
2019 1
2020 1
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Schalck A, et al. Among authors: sakellariou thompson d. Cancer Discov. 2022 Oct 5;12(10):2330-2349. doi: 10.1158/2159-8290.CD-21-1248. Cancer Discov. 2022. PMID: 35849783 Free PMC article.
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Amaria R, et al. Among authors: sakellariou thompson d. J Immunother Cancer. 2024 Feb 2;12(2):e006822. doi: 10.1136/jitc-2023-006822. J Immunother Cancer. 2024. PMID: 38309721 Free PMC article.
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA. Fix SM, et al. Among authors: sakellariou thompson d. J Immunother Cancer. 2022 Jul;10(7):e003750. doi: 10.1136/jitc-2021-003750. J Immunother Cancer. 2022. PMID: 35882447 Free PMC article.
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Shah P, et al. Among authors: sakellariou thompson d. J Immunother Cancer. 2022 Feb;10(2):e003082. doi: 10.1136/jitc-2021-003082. J Immunother Cancer. 2022. PMID: 35110355 Free PMC article.
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Mitra A, et al. Among authors: sakellariou thompson da. Nat Commun. 2020 Apr 15;11(1):1839. doi: 10.1038/s41467-020-15538-9. Nat Commun. 2020. PMID: 32296058 Free PMC article.
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C. Tavera RJ, et al. Among authors: sakellariou thompson d. J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230. J Immunother. 2018. PMID: 29757889 Free PMC article. Clinical Trial.
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Forget MA, et al. Among authors: sakellariou thompson d. Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30. Clin Cancer Res. 2018. PMID: 29848573 Free PMC article.
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.
Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. Sakellariou-Thompson D, et al. Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25. Clin Cancer Res. 2017. PMID: 28947567 Free PMC article.